Barclays’s Aratana Therapeutics, Inc. PETX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q3 | – | Sell |
-31,187
| Closed | -$161K | – | 7467 |
|
|
2019
Q2 | $161K | Buy |
31,187
+13,915
| +81% | +$62.5K | ﹤0.01% | 5301 |
|
|
2019
Q1 | $62K | Buy |
17,272
+15,386
| +816% | +$66.7K | ﹤0.01% | 5723 |
|
|
2018
Q4 | $11K | Sell |
1,886
-15,263
| -89% | -$93.1K | ﹤0.01% | 6156 |
|
|
2018
Q3 | $100K | Buy |
17,149
+13,871
| +423% | +$69.3K | ﹤0.01% | 5552 |
|
|
2018
Q2 | $14K | Sell |
3,278
-10,522
| -76% | -$53.1K | ﹤0.01% | 6394 |
|
|
2018
Q1 | $61K | Buy |
13,800
+7,065
| +105% | +$31.5K | ﹤0.01% | 5760 |
|
|
2017
Q4 | $36K | Buy |
6,735
+5,244
| +352% | +$32.1K | ﹤0.01% | 5959 |
|
|
2017
Q3 | $9K | Sell |
1,491
-3,205
| -68% | -$20.3K | ﹤0.01% | 6209 |
|
|
2017
Q2 | $34K | Sell |
4,696
-10,855
| -70% | -$66.8K | ﹤0.01% | 5552 |
|
|
2017
Q1 | $83K | Buy |
15,551
+14,312
| +1,155% | +$96.6K | ﹤0.01% | 5022 |
|
|
2016
Q4 | $9K | Sell |
1,239
-1,591
| -56% | -$12.9K | ﹤0.01% | 5960 |
|
|
2016
Q3 | $26K | Buy |
2,830
+2,348
| +487% | +$19.5K | ﹤0.01% | 5346 |
|
|
2016
Q2 | $3K | Buy |
482
+300
| +165% | +$1.93K | ﹤0.01% | 5891 |
|
|
2016
Q1 | $1K | Sell |
182
-304
| -63% | -$1.14K | ﹤0.01% | 6054 |
|
|
2015
Q4 | $2K | Sell |
486
-9,422
| -95% | -$62.3K | ﹤0.01% | 5778 |
|
|
2015
Q3 | $80K | Buy |
9,908
+9,307
| +1,549% | +$158K | ﹤0.01% | 4755 |
|
|
2015
Q2 | $9K | Sell |
601
-651
| -52% | -$9.4K | ﹤0.01% | 6160 |
|
|
2015
Q1 | $20K | Sell |
1,252
-8,084
| -87% | -$144K | ﹤0.01% | 5842 |
|
|
2014
Q4 | $159K | Sell |
9,336
-200,951
| -96% | -$2.5M | ﹤0.01% | 4823 |
|
|
2014
Q3 | $2.1M | Buy |
210,287
+209,765
| +40,185% | +$2.54M | ﹤0.01% | 2618 |
|
|
2014
Q2 | $7K | Buy |
522
+183
| +54% | +$2.59K | ﹤0.01% | 7022 |
|
|
2014
Q1 | $6K | Sell |
339
-779
| -70% | -$15.6K | ﹤0.01% | 7160 |
|
|
2013
Q4 | $20K | Buy |
1,118
+557
| +99% | +$11.3K | ﹤0.01% | 6724 |
|
|
2013
Q3 | $9K | Buy |
+561
| New | +$5.89K | ﹤0.01% | 6834 |
|
Other funds holding PETX
Barclays's PETX Position: Q3 2019 in Review
Barclays sold out of Aratana Therapeutics, Inc. (PETX) in Q3 2019, closing a stake of 31,187 shares — an estimated $161K sold.
Barclays first reported a position in PETX in Q3 2013 and held it in 24 quarters. The position peaked at $2.1M in Q3 2014. 2 funds tracked by Wall St. Rank hold PETX as of Q3 2019.
- Barclays reported no remaining Aratana Therapeutics, Inc. position as of Q3 2019 after selling out during the quarter.
- Barclays sold 31,187 Aratana Therapeutics, Inc. shares in Q3 2019, an estimated $161K.
- Barclays first reported a position in Aratana Therapeutics, Inc. in Q3 2013 and held it in 24 quarters.
- Barclays's Aratana Therapeutics, Inc. position peaked at $2.1M in Q3 2014.
- 2 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q3 2019.
Based on Barclays's 13F filing for Q3 2019, filed 14 Nov 2019.